– Firm isn’t providing shares pursuant to the registration assertion –
MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Firm”) (NASDAQ:BRTX), a medical stage firm centered on stem cell-based therapies, right this moment introduced the submitting of a registration assertion on Kind S-1 with the Securities and Change Fee (the “SEC”). The registration assertion solely covers the resale by promoting securityholders of as much as 2,513,686 shares of widespread inventory of the Firm which might be issuable pursuant to the train of beforehand issued warrants. The submitting was made pursuant to registration rights granted to the promoting securityholders in reference to the issuance of the warrants to them.
The Firm’s Kind S-1 registration assertion has been filed with the SEC however has not but grow to be efficient. A duplicate of the Kind S-1 submitting will be seen on the SEC’s web site at www.sec.gov, or will be obtained upon written request to the Firm at 40 Marcus Drive, Suite One, Melville, New York, 11747, Consideration: Secretary.
These shares might not be offered nor might presents to purchase be accepted previous to the time the registration assertion turns into efficient. This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase, nor shall there be any sale of those shares in any state wherein such supply, solicitation or sale could be illegal previous to registration or qualification underneath the securities legal guidelines of any state.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic merchandise utilizing cell and tissue protocols, primarily involving grownup stem cells. Our two core applications, as described under, relate to the remedy of disc/backbone illness and metabolic issues:
• Disc/Backbone Program (brtxDISC): Our lead cell remedy candidate, BRTX-100, is a product formulated from autologous (or an individual’s personal) cultured mesenchymal stem cells collected from the affected person’s bone marrow. We intend that the product might be used for the non-surgical remedy of painful lumbosacral disc issues or as a complementary therapeutic to a surgical process. The BRTX-100 manufacturing course of makes use of proprietary expertise and includes accumulating a affected person’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient process, BRTX-100 is to be injected by a doctor into the affected person’s broken disc. The remedy is meant for sufferers whose ache has not been alleviated by non-invasive procedures and who doubtlessly face the prospect of surgical procedure. We have now commenced a Section 2 medical trial utilizing BRTX-100 to deal with power decrease again ache arising from degenerative disc illness.
• Metabolic Program (ThermoStem®): We’re growing a cell-based remedy candidate to focus on weight problems and metabolic issues utilizing brown adipose (fats) derived stem cells to generate brown adipose tissue (“BAT”). BAT is meant to imitate naturally occurring brown adipose depots that regulate metabolic homeostasis in people. Preliminary preclinical analysis signifies that elevated quantities of brown fats in animals could also be chargeable for further caloric burning in addition to diminished glucose and lipid ranges. Researchers have discovered that folks with increased ranges of brown fats might have a diminished danger for weight problems and diabetes.
Ahead-Trying Statements
This press launch incorporates “forward-looking statements” throughout the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Change Act of 1934, as amended, and such forward-looking statements are made pursuant to the secure harbor provisions of the Non-public Securities Litigation Reform Act of 1995. You might be cautioned that such statements are topic to a mess of dangers and uncertainties that might trigger future circumstances, occasions or outcomes to vary materially from these projected within the forward-looking statements because of varied components and different dangers, together with, with out limitation, these set forth within the Firm’s newest Kind 10-Ok filed with the Securities and Change Fee. It’s best to think about these components in evaluating the forward-looking statements included herein, and never place undue reliance on such statements. The forward-looking statements on this launch are made as of the date hereof and the Firm undertakes no obligation to replace such statements.
CONTACT:
E mail: ir@biorestorative.com
The submit BioRestorative Therapies Proclaims Submitting of Kind S-1 Registration Assertion to Register for Resale Frequent Inventory Underlying Beforehand Issued Warrants appeared first on FinanceGrabber.